Electronic Arts Inc. (EA)

$EA
Target Raised by Wells Fargo Equal Weight USD 145 » USD 165
Target Raised by Piper Sandler In-Line » Neutral USD 133 » USD 156
Target Raised by Barclays In-Line » Equal Weight USD 124 » USD 145

Why SENS will dominate DEXCOM AND ABBOTT CGM in 3 to 5 years!

CGM market is still in infancy. DXCOM, Abbott, Medtronic and Roche only grabbed <10% of CGM market today; the total number of possible diabetics who needs this device are enormous. More and more insurance companies are buying into importance of CGM capabilities in reducing medical complications. The total costs related to diabetes costs just in America annually is Hundreds of billions of dollars each year. It’s much cheaper for insurance companies to pay upfront fees to get CGM implanted then pay for treatments for leg amputations, diabetes blindness, end stage kidney failures, cardiac complications secondary to untreated diabetes. There are many more conditions causing billions of dollars in Medicare due to uncontrolled diabetes. CGM device is literally life savers for millions of people around the world. Currently there is vast untapped markets for both internal and external CGMs in India, China, Middle East, Far East, South America. CGM growth will be exponential over the next decades. Lastly, Medicare will be paying Providers almost twice more to implant Eversense CGM then Dexcom CGM. Main reasons for this? It cheaper in the long run to implant Eversense CGM. Dexcom requires very expensive external sensors changing out every 7 to 10 days. Eversense CGM, no sensor change needed during lifetime of Eversense implant. Great bargain compare to Dexcom G6 or Abbott Libre